Patients with colon cancer that spread to the liver had few options if standard chemotherapy stopped working. Now, a treatment that pumps chemo directly to the tumor is doubling the survival rate and giving patients precious time.
Rita LaFlamme has 57 years of memories and counting with her husband Bob.
“We have two sons and two grandchildren,” said LaFlamme.
Get connected to a healthier life.
But both were stunned when LaFlamme was diagnosed with stage four colorectal cancer last year. Every year, nearly 140-thousand people in the U.S. are diagnosed with colorectal cancer. In up to a quarter of those, it has spread to the liver.
When standard chemotherapy stops working many patients are left with few options. Now doctors at Duke University are offering a treatment called hepatic artery infusion using a pump.
“The pump which is a battery powered motorized pump is surgically implanted into a pocket in the abdominal wall,” Dr. Michael Lidsky, a Surgical Oncologist at Duke University Medical Center explained.
The pump provides a direct dose of concentrated chemo to the liver.
“Those concentrations actually reach somewhere between three and 400 times the concentration that we would be able to get if we gave it intravenously,” Lidsky said.
So far, the results have been dramatic. Lidsky says the treatment is used in combination with standard chemo and has been shown to double the survival rate.
“It’s pumping on the tumor and I’m not feeling a thing,” said LaFlamme.
LaFlamme says the treatment is working to shrink her tumor and she hopes to have surgery to remove it soon.
“I know I can beat this. I have no doubt in my mind that I will, I will beat it,” LaFlamme said.
More time means more memories for LaFlamme.
Lidsky says hepatic artery infusion is not a cure but can be used pre or post surgery to shrink tumors in patients with metastatic colorectal cancer to the liver. Right now, the treatment is only being offered at a handful of centers around the country including Duke and Memorial Sloan Kettering in New York.
The pump stays in the patient for years and can be used again if the disease recurs. Patients need to be fit and have liver-dominant disease only to be a good candidate. For more information go to DukeHealth.org.
Contributors to this news report include: Janna Ross, Field Producer; Cyndy McGrath, Supervising Producer; Kirk Manson, Videographer; Roque Correa, and Editor.